July 24, 2018 Bio/Pharma/CRO M&A, Partnerships

Pall Corporation and BioSciencesCorp Launch Strategic Partnership to Support Industry Drive Towards Integrated End-to-End Bioprocessing

PORT WASHINGTON, N.Y., July 24, 2018 /PRNewswire/ — Pall Corporation, a global leader in filtration, separation and purification, is partnering with BioSciencesCorp, a consulting company providing novel biologics and biosimilars process know-how and regulatory experience from molecule selection to full commercialization. Together they will deliver cost-effective manufacturing strategies, and efficient upstream and downstream process equipment and facility design... Read more

July 22, 2018 Bio/Pharma/CRO Licensing, IP, and Legal Life Science Tools

Gyros Protein Technologies and Cygnus Technologies sign licensing and supply agreement

Uppsala, Sweden and Southport, N.C., July 10, 2018: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, today announced they have signed a licensing and supply agreement. Under the... Read more

July 19, 2018 Bio/Pharma/CRO Chromatography Environ, Ag./Food & Bev Lab Top-10 Product Launch

New Luna Omega HILIC Column Delivers Increased LC Separation of Sugars

Torrance, Calif. (July 19, 2018) – Phenomenex Inc., global leader in the research, design and manufacture of advanced technologies for the separation sciences, announces a new Luna Omega phase for sugar analysis by hydrophilic interaction chromatography (HILIC). Luna Omega SUGAR is specifically engineered for carbohydrate separation and analysis from food, beverage and pharmaceutical matrices, such as milk, animal... Read more

July 19, 2018 Bio/Pharma/CRO

Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer

Basel, 19 July 2018 Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated... Read more

July 18, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

Basel, 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)... Read more

July 17, 2018 Bio/Pharma/CRO PR/Corporate

Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu

Basel, 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in... Read more

July 17, 2018 Bio/Pharma/CRO PR/Corporate

Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu

Basel, 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in... Read more

July 10, 2018 Bio/Pharma/CRO M&A, Partnerships Mass Spectrometry

908 Devices and Hangzhou Just Biotherapeutics Announce Joint Innovation Partnership

07.10.18 908 Devices, a pioneer of purpose-built analytical devices for chemical and biomolecular analysis, today announced a joint innovation partnership with Hangzhou Just Biotherapeutics (HJB). HJB is an integrated design company focused on technologies that will accelerate development of biotherapeutics and reduce manufacturing costs to make medicines more readily available in the global marketplace. HJB partners... Read more

July 2, 2018 Atomic Spectroscopy Bio/Pharma/CRO Cell Analysis Tools Chromatography Lab Equipment Lab Top-10 Life Science Tools Molecular Spectroscopy

MilliporeSigma to Expand Operations in Gillingham, UK

Jul 02, 2018 Company to expand distribution centre for Life Science products to support future business growth MilliporeSigma, a leading science and technology company, today announced plans to expand its Gillingham, UK distribution centre. The €9 million investment will boost distribution capabilities for the business. Anticipated to open in early 2019, the new facility will... Read more

July 2, 2018 Bio/Pharma/CRO Licensing, IP, and Legal PR/Corporate

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Basel, 02 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple... Read more